ロード中...
Tamoxifen Initiation After Ductal Carcinoma In Situ
BACKGROUND. Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly variable and largely unexplained. National guidelines recommend considering tamoxifen for women with estrogen receptor-positive (ER+) DCIS or who undergo excision alone. We evaluated endocrine therapy use after...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4746086/ https://ncbi.nlm.nih.gov/pubmed/26768485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0310 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|